Last update 12 Jul 2024

Lisocabtagene maraleucel

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
anti-CD19-EGFRt-4-1BB-zeta modified CAR CD8+ and CD4+ T lymphocyte therapy, anti-CD19/EGFRt/4-1BB/zeta modified CAR CD8+ and CD4+ T lymphocyte therapy, CD19-directed chimeric antigen receptor T cell therapy
+ [6]
Target
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators), T lymphocyte replacements
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
RegulationPriority Review (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D11990--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Mantle-Cell Lymphoma
US
31 May 2024
Chronic Lymphocytic Leukemia
US
18 Mar 2024
Large B-cell lymphoma
US
18 Mar 2024
Small Lymphocytic Lymphoma
US
18 Mar 2024
B-Cell Lymphoma
EU
25 May 2023
B-Cell Lymphoma
IS
25 May 2023
B-Cell Lymphoma
LI
25 May 2023
B-Cell Lymphoma
NO
25 May 2023
Refractory High-Grade B-Cell Lymphoma
EU
25 May 2023
Refractory High-Grade B-Cell Lymphoma
IS
25 May 2023
Refractory High-Grade B-Cell Lymphoma
LI
25 May 2023
Refractory High-Grade B-Cell Lymphoma
NO
25 May 2023
Diffuse large B-cell lymphoma recurrent
EU
04 Apr 2022
Diffuse large B-cell lymphoma recurrent
IS
04 Apr 2022
Diffuse large B-cell lymphoma recurrent
LI
04 Apr 2022
Diffuse large B-cell lymphoma recurrent
NO
04 Apr 2022
Diffuse large B-cell lymphoma refractory
EU
04 Apr 2022
Diffuse large B-cell lymphoma refractory
IS
04 Apr 2022
Diffuse large B-cell lymphoma refractory
LI
04 Apr 2022
Diffuse large B-cell lymphoma refractory
NO
04 Apr 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mantle cell lymphoma recurrentNDA/BLA
US
30 Jan 2024
Mantle cell lymphoma recurrentNDA/BLA
JP
30 Jan 2024
Mantle cell lymphoma refractoryNDA/BLA
US
30 Jan 2024
Mantle cell lymphoma refractoryNDA/BLA
JP
30 Jan 2024
Recurrent Follicular LymphomaNDA/BLA
US
30 Jan 2024
Recurrent Follicular LymphomaNDA/BLA
JP
30 Jan 2024
Refractory Follicular LymphomaNDA/BLA
US
30 Jan 2024
Refractory Follicular LymphomaNDA/BLA
JP
30 Jan 2024
Chronic lymphocytic leukaemia refractoryNDA/BLA
US
18 Nov 2023
Recurrent Chronic Lymphoid LeukemiaNDA/BLA
US
18 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
30
zfwcwnppen(zerbytgkfj) = wzclwgcmwc rqpwivaowy (clhykqoutq )
Positive
24 May 2024
Phase 1
88
rydrlbdcop(fyckgnvize) = jfnxhpqemc bufihaspzg (kyydhabgtx )
Positive
24 May 2024
(Prior LOT ≥ 2)
rydrlbdcop(fyckgnvize) = wqpiukyedj bufihaspzg (kyydhabgtx )
Phase 3
184
oivbvfwfjw(etahcyzbwh) = bfzhkjnboq oakcayaalc (whlgqkegrf )
Positive
24 May 2024
SOC
oivbvfwfjw(etahcyzbwh) = tktmvzrjjx oakcayaalc (whlgqkegrf )
Phase 2
Second line
139
Bridging Therapy (BT)
vqtoetnldv(pgiuxsthye) = mkvwfbqtez lrwmwerpkz (dmsrxczcwr )
Positive
24 May 2024
No Bridging Therapy (NBT)
vqtoetnldv(pgiuxsthye) = xmjxdexnsb lrwmwerpkz (dmsrxczcwr )
Phase 1
Mantle-Cell Lymphoma
Bruton tyrosine kinase inhibitor (BTKi) | alkylating agent | CD20-targeted agent ...
104
cayuyqjpzg(qgacyaezfb) = odaohybktj lenwqihinp (lavlwkmlhe, 73.3 - 90.5)
Positive
01 Apr 2024
Lisocabtagene maraleucel 100 × 106
cayuyqjpzg(qgacyaezfb) = fpnefwztin lenwqihinp (lavlwkmlhe, 73.3 - 90.5)
Not Applicable
270
Lisocabtagene maraleucel (liso-cel)
lzjnmnvpef(ufrzjhkmnb) = pkxqximsmd wnbbhhgolp (jnkogwkiqa )
Positive
01 Feb 2024
Phase 2
130
ypczqnjkev(enmyyouqoc) = hfizdeacqp dfwkcflzrc (hhpxfdxwfb )
-
11 Dec 2023
Phase 2
25
mxwtlunhrc(fjxqzledem) = whaqwfifds mjtwficjab (vvplahsgmi, 78.1 - 99.9)
Positive
10 Dec 2023
Not Applicable
96
fwvngsqfhc(jzectvzgdk) = tanbtrxxlv drlzrohrll (rzhwazqbrh )
-
10 Dec 2023
Not Applicable
101
weqmfzfrce(qeytfmssmi) = jjfcdqbgfh oxoxrqfrdq (ypiwstmnrb )
-
10 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free